Cytosorbents (NASDAQ:CTSO) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the medical research company’s stock.

Several other brokerages have also recently commented on CTSO. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Thursday, May 15th. Wall Street Zen assumed coverage on shares of Cytosorbents in a research report on Wednesday, May 21st. They set a “hold” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Cytosorbents Stock Down 17.2%

Shares of NASDAQ:CTSO opened at $0.8939 on Wednesday. Cytosorbents has a one year low of $0.7101 and a one year high of $1.61. The company has a 50 day moving average of $1.06 and a 200-day moving average of $1.03. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.34 and a quick ratio of 1.96. The stock has a market cap of $56.10 million, a price-to-earnings ratio of -5.26 and a beta of 1.19.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. The company had revenue of $9.62 million during the quarter, compared to analysts’ expectations of $9.79 million. On average, sell-side analysts forecast that Cytosorbents will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CTSO. Avenir Corp grew its holdings in Cytosorbents by 63.1% during the first quarter. Avenir Corp now owns 5,044,918 shares of the medical research company’s stock valued at $5,045,000 after purchasing an additional 1,950,972 shares during the period. CM Management LLC grew its holdings in Cytosorbents by 36.3% during the first quarter. CM Management LLC now owns 954,076 shares of the medical research company’s stock valued at $954,000 after purchasing an additional 254,076 shares during the period. Skylands Capital LLC grew its holdings in Cytosorbents by 7.9% during the first quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company’s stock valued at $3,003,000 after purchasing an additional 221,080 shares during the period. Raymond James Financial Inc. acquired a new position in Cytosorbents during the fourth quarter valued at approximately $99,000. Finally, Key Client Fiduciary Advisors LLC grew its holdings in Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock valued at $78,000 after purchasing an additional 43,900 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.